Patient information
| Group | Immune tolerant | Immune activation | AR | CR | HC |
| Cases | 6 | 5 | 3 | 3 | 6 |
| Age (years) | 34 (21–55) | 29 (25–45) | 37 (28–45) | 47 (45–49) | 52 (33–66) |
| Sex (M/F) | 4/2 | 4/1 | 2/1 | 3/0 | 4/2 |
| Time since HBV diagnosis (years) | 14.7 (1.5–27.0) | 20 (10–20) | <0.5 | 10 (1–20) | NA |
| HBsAg level (IU/mL) | 40 636 (5652–69 050) | 7881 (833.2–32 970.0) | 783 (0–1293) | <0.05 | NA |
| HBV DNA level (log10 IU/mL) | 8.328 (8–8.88) | 6.761 (5.29–8) | 0.9783 (0–2.935) | LDL | NA |
| ALT (U/L) | 36.1 (20–45.7) | 232.2 (60–424) | 108 (25–192) | 18.67 (13–22) | 20.8 (11–31) |
| AST (U/L) | 28.7 (19–42) | 91.2 (34–129) | 44 (21–58) | 19 (16–24) | 19 (15–27) |
ALT, alanine aminotransferase; AR, acute recovery; AST, aspartate transaminase; CR, chronic resolved ; F, female; HBsAg, HBV surface antigen; HC, healthy control; LDL, lower detection limit; M, male; NA, not applicable.